GEN Exclusives

More »

GEN News Highlights

More »
Mar 18, 2009

Biokine Receives $1.2M to Develop Myeloma Treatment

Biokine Receives $1.2M to Develop Myeloma Treatment

Israeli government issues grant to Biokine for clinical trial of BKT140

  • Biokine Therapeutics begun a Phase I/IIa study of BKT140, a myeloma treatment, at Chaim Sheba Medical Center in Tel-Hasomer, Israel, after receiving a $1.2 million grant from the office of the chief scientist of the Israeli ministry of industry, trade and labor.

    The firm says that in experimental models, BKT140 promoted normal cell production in bone marrow and their entry into the blood while initiating death and removal of myeloma and leukemia cells.

    Biokine, founded in 2000 in Israel, focuses on the development of pharmaceuticals that control the activity of receptors for the chemokine CXCR4.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?